Cure8
Long-term clinical outcomes of stem cell-based interventions in Crohn's-related perianal fistula: A systematic review and meta-analysis.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Cure8 research brief

Long-term clinical outcomes of stem cell-based interventions in Crohn's-related perianal fistula: A systematic review and meta-analysis.

2 min read
Procedures and surgery Fistula Systematic Review or Meta Analysis Patients On Biologics Post Surgery Patients Clinicians Researchers Crohn's disease

Why This Matters

Perianal fistulas in Crohn’s disease are often hard to treat; this review suggests stem cell therapies can produce durable closure for many patients and appear safe over 1–4 years of follow-up.

Who Should Pay Attention

Patients with Crohn’s disease and persistent perianal fistulas, colorectal surgeons and IBD clinicians considering advanced therapies, and researchers studying cell-based treatments for IBD complications.

Study Snapshot

Story typeResearch paper
Evidence typeSystematic review
Source depthJournal abstract

What To Know

This paper pooled data from 18 studies (750 patients) including randomized trials and observational/early-phase studies, with follow-up from 12 months to 4 years. In the restricted analysis of randomized controlled trials the long-term clinical healing rate was about 59% (95% CI 51%–67%).

An exploratory pooled estimate across all study designs was about 63%, but that mixed different study types. The review reports generally favorable safety outcomes: no treatment-related deaths and no clearly therapy-associated malignancies were identified across included studies.

Observational and early-phase studies showed more variable results and a higher risk of bias compared with RCTs. How to use this information This is a synthesis of available longer-term data, not a treatment guideline.

Patients and clinicians should view these pooled rates as encouraging but influenced by differences in study design, patient selection, and stem cell products used. Discuss individual suitability, product availability, and local expertise with a colorectal specialist or IBD team.

Keep In Mind

The paper is a systematic review and meta-analysis based on studies through Sept 1, 2024, including RCTs and observational/early-phase trials. The exploratory pooled estimate mixes study designs and should be interpreted cautiously because of heterogeneity and variable risk of bias.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Systematic review Evidence type derived from source or registry metadata.
PublicationColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
AuthorsHeidari M, Azizpour AM, Rayatpisheh M +3 more
Study typeMeta Analysis, systematic review, review, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedOct 1, 2026, 12:00 AM
Content availableJournal abstract

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →